ArticleArchives of gynecology and obstetrics2022
The web-based application "QUiPP v.2" for the prediction of preterm birth in symptomatic women is not yet ready for worldwide clinical use: ten reflections on development, validation and use.
Article in Archives of gynecology and obstetrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 15 citations in OpenAlex.
- Repeated Quantitative Fetal Fibronectin Assessments for Preterm Birth Prediction in Pregnant Women with Cervical Insufficiency.Diagnostics (Basel, Switzerland) · 2026Article
- The utility of combined utero-cervical ındex in predicting preterm delivery in pregnant women with preterm uterine contractions.Archives of gynecology and obstetrics · 2024Article
- Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn this correspondence, we highlight general and domain-specific caveats in the development and validation of prediction models.
methodsDevelopment and use of the "QUiPP" application, a tool for preterm birth prediction which is supported by the United Kingdom National Health Service, is scrutinised and commented on.
resultsWe highlight and elaborate ten points which may be perceived to be unclear or potentially misleading.
conclusionWhile the QUiPP application has high potential, it lacks transparency (on certain aspects related to model development) and proper validation. This precludes transportability to settings with other treatment policies and to other countries where the app has been made publicly available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.